Mission Therapeutics, a Cambridge, UK-based drug discovery and development company, has appointed Dr Colin Goddard, former Chief Executive of OSI Pharmaceuticals, to its Board of Directors.
Dr Goddard joined OSI as a research scientist in 1989 and led the transformation of the technology platform services company into a profitable fully integrated biopharmaceutical organisation, becoming CEO in 1998. He was pivotal in the registration and launch of OSI’s targeted therapeutic product, Tarceva (erlotinib) and also directed the company’s financing, corporate development and acquisition strategies, completing several major acquisitions and divestitures and raising more than US$1.5bn in capital. OSI was acquired by Astellas Pharma in June 2010 for $4bn.
Dr Goddard obtained his PhD in cancer pharmacology from the University of Aston in Birmingham, UK and worked at the National Cancer Institute, Bethesda, MD, US before joining OSI. He currently serves as Executive Chairman of US based Biotech companies, Coferon and Merganser Biotech, and as a Director on the boards of Endocyte and PanOptica. He was formerly a Director at Human Genome Sciences.
